Sinolink Securities Co., Ltd. has released a research report indicating that orthopedic surgery robots are transitioning from a supply expansion phase, driven by regulatory approvals, into a commercialization validation phase, backed by increased installation and usage. The establishment of a national unified pricing framework and the accelerated implementation at the local level provide a clearer institutional foundation for commercial scaling. The firm believes that 2026 will be a critical window for the accelerated rollout of fee schedules and the validation of business models, with 2027 expected to further confirm improvements in equipment utilization rates and corporate operational flexibility.
While the global market has entered a phase of large-scale application, China remains in a period of low penetration but high growth. The market size for orthopedic surgery robots in China is projected to maintain a growth rate of approximately 40% annually from 2024 to 2026.
Key Insights from the Report
The global orthopedic surgery robot market has evolved from technology validation and major mergers and acquisitions to indication expansion and ecosystem-based operations. Platforms such as Stryker's MAKO, Medtronic's Mazor, and Zimmer Biomet's ROSA have progressively matured. Significant domestic market expansion in China began primarily after 2021, driven by a wave of domestic product approvals and the entry of international leaders. From 2023 to 2025, sales of orthopedic surgery robots in public procurement samples increased from 58 units to 115 units, nearly doubling in two years. As product supply diversifies, hospital awareness improves, and bidding processes advance, market procurement is accelerating.
Domestic product offerings are continuously expanding, and the industry value chain is extending toward the full lifecycle of the equipment. The clinical characteristics and commercialization pathways differ across the three main sub-sectors: joint replacement, spine, and trauma. Joint replacement procedures are relatively standardized, and robots can create strong synergies with implants and consumables, offering a clearer path for large-scale promotion and recurring revenue. Spine surgery demands higher precision in navigation, intraoperative imaging, surgeon experience, and training services, which is expected to drive the integrated development of navigation, imaging, implants, and technical services. The trauma field covers a wide range of procedures, and as indications expand, the application scenarios for robots are also expected to diversify. Concurrently, a tiered pricing structure is emerging, which can help lower the purchasing threshold for hospitals of different levels. Future industry growth will no longer rely solely on one-time equipment sales but will gradually shift towards implants, specialized consumables, maintenance services, software upgrades, and clinical training, thereby increasing the total lifetime value of each device.
Improved Payment Environment Expected to Catalyze Commercial Deployment
Since 2021, the pace of approvals from the National Medical Products Administration (NMPA) has accelerated significantly, with new products predominantly from domestic manufacturers. The industry has moved from isolated product breakthroughs to a phase of concentrated approvals for multiple companies. The regulatory focus has also evolved from simply encouraging innovation and expediting market entry to a comprehensive lifecycle management approach covering registration review, quality systems, and post-market surveillance. On the payment side, the National Healthcare Security Administration has established a unified pricing framework categorized by navigation, assisted execution, and precise execution. This framework helps to streamline the process for local governments to set prices and provides a basis for aligning with medical insurance reimbursements. As local pricing policies are implemented more quickly, hospital purchasing enthusiasm, patient access, and clinical equipment utilization rates are expected to improve in tandem.
Companies with Early Install Base and Platform Ecosystem
Among international companies, Stryker has built a 'robot + implant + consumable + digital service' ecosystem around its MAKO platform, providing a mature business model for domestic firms to reference. For domestic original equipment manufacturers (OEMs), the report suggests focusing on companies with a strong early-install base, a multi-indication product portfolio, and the ability to innovate business models. Attention should also be paid to companies with platform-based product matrices and international capabilities, as well as those in the industrial chain with an established implant business that can promote a 'robot + implant' synergy. The report concludes that platform-based companies with clinical foundations, comprehensive product matrices, supply chain control, and ecosystem integration capabilities are better positioned to achieve faster revenue growth and improved profitability during the industry's scaling phase.
Risk Factors
Risks include slower-than-expected progress in medical insurance payment and pricing policy implementation; slower-than-expected hospital procurement and installation pace; lower-than-expected clinical penetration rate increases; intensified industry competition impacting profitability; risks related to core technology iteration and product development; and slower-than-expected progress in domestic substitution.